Literature DB >> 19476016

Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents.

J Seidenberg1, G Battista Pajno, C P Bauer, S La Grutta, J Sieber.   

Abstract

OBJECTIVE: We conducted a large observational study in 193 children and adolescents with allergic rhinitis due to grass or tree pollens to evaluate the safety and tolerability of an ultrarush high-dose sublingual immunotherapy (SLIT) regimen reaching a maintenance dose of 300 index of reactivity within 90 minutes.
METHODS: Children and adolescents aged 5 to 17 years with at least a 1-year medical history of allergic rhinitis with or without mild to moderate asthma due to tree pollens (birch, alder, hazel) or grass pollens (cocksfoot, meadow grass, rye grass, sweet vernal grass, timothy) were recruited. Standardized grass and tree pollen allergen extracts were used for ultrarush titration and subsequent coseasonal maintenance.
RESULTS: During ultrarush titration, 60 patients (31%) reported 117 predominantly mild and local adverse events, which resolved within 150 minutes. During the maintenance phase, 562 adverse events were reported; the most frequent local events were oral pruritus, burning sensation, lip or tongue swelling, and gastrointestinal symptoms, and the most frequent systemic events were rhinoconjunctivitis and asthma. There was 1 clinically significant asthma event in an 11-year old boy with known asthma in whom SLIT was resumed after an interval of 4 days.
CONCLUSION: Ultrarush titration was safe and well tolerated. Pediatric patients with asthma should be carefully monitored and adequately trained to use their rescue medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19476016

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  9 in total

1.  Sublingual immunotherapy in patients with allergic rhinoconjunctivitis.

Authors:  Deborah Gentile; David P Skoner
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

Review 2.  Immunotherapy for allergies and asthma: present and future.

Authors:  Shyam S Mohapatra; Momina Qazi; Gary Hellermann
Journal:  Curr Opin Pharmacol       Date:  2010-06-21       Impact factor: 5.547

Review 3.  Immunotherapy in all aspects.

Authors:  Deniz Hanci; Ethem Şahin; Nuray Bayar Muluk; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-12       Impact factor: 2.503

4.  Therapeutic effects and biomarkers in sublingual immunotherapy: a review.

Authors:  Takashi Fujimura; Yoshitaka Okamoto; Masaru Taniguchi
Journal:  J Allergy (Cairo)       Date:  2012-03-05

5.  Safety and efficacy of tree pollen specific immunotherapy on the ultrarush administration schedule method using purethal trees.

Authors:  Andrzej Bozek; Krzysztof Kolodziejczyk; Jerzy Jarzab
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

Review 6.  Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children.

Authors:  Sophia Tsabouri; Antigoni Mavroudi; Gavriela Feketea; George V Guibas
Journal:  Front Pediatr       Date:  2017-04-21       Impact factor: 3.418

Review 7.  A critical appraisal on AIT in childhood asthma.

Authors:  Matteo Ferrando; Francesca Racca; Lorena Nascimento Girardi Madeira; Enrico Heffler; Giovanni Passalacqua; Francesca Puggioni; Niccolò Stomeo; Giorgio Walter Canonica
Journal:  Clin Mol Allergy       Date:  2018-03-06

Review 8.  Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose.

Authors:  Pascal Demoly; Gianni Passalacqua; Moises A Calderon; Tarik Yalaoui
Journal:  Clin Transl Allergy       Date:  2015-12-23       Impact factor: 5.871

Review 9.  How does the efficacy and safety of Oralair(®) compare to other products on the market?

Authors:  Désirée Larenas-Linnemann
Journal:  Ther Clin Risk Manag       Date:  2016-05-27       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.